WO1997017976A1 - Microcellulose-based preparations - Google Patents
Microcellulose-based preparations Download PDFInfo
- Publication number
- WO1997017976A1 WO1997017976A1 PCT/EP1996/004961 EP9604961W WO9717976A1 WO 1997017976 A1 WO1997017976 A1 WO 1997017976A1 EP 9604961 W EP9604961 W EP 9604961W WO 9717976 A1 WO9717976 A1 WO 9717976A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microcellulose
- fibres
- preparations
- intestinal
- effect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Definitions
- dietary fibres the main indigestible alimentary constituent
- dietary fibres have found a wide application in the treatment of constipation.
- the term dietary fibres is referred to the total natural fibrosic contents available in aliments, mainly of vegetable origin, which cannot be chemically digested by the enzymatic system of humans.
- classification of dietary fibres is referred to the residues of indigestible vegetables and can be summarized as follows:
- Cellulose is a polysaccharide (C 6 H ⁇ o0 5 ) whose molecular weight ranges from 300.000 to 500.000, formed by linear chains of D- glucose molecules linked together by beta bonds.
- Alimentary fibres consist of millions of cellulose molecules linked together in chains, whose length may even reach several tens of centimeters or meters. Beta bonds are undigested by mammals " enzymatic systems (for instance, starch has alpha bonds).
- Cellulose is the main structural constituent of vegetable cell walls. It is insoluble in distilled water and acids.
- Non-cellulosic fibres consist of non-cellulosic polysaccharides comprising emicelluloses, pectines, mucillages and other media derived by algae, resins and lignin. Besides water absorption, non-cellulosic fibres have also other collateral effects due to their chelant action as they seem to be able to chelate biliary salts and cholesterol, thus reducing their abso ⁇ tion; however, this effect is unfortunately reached also with drugs and minerals, such as iron, calcium and zinc. Further, resins and soluble fibres contained therein may undergo a bacterial digestion in the colon, and elicit short-chain volatile fat acids and gas production (carbon dioxide and methane).
- Methyl-cellulose and carboxymethyl-cellulose derived from it are products obtained by synthesis, which modify the chemical- physical characteristics of cellulose, i.e. from insoluble to soluble in cold water and insoluble in hot water.
- Solubility is a function of the number of methylic units used as substituents; the products known on the market have a 1,8 substitution degree, i.e. they contain about 29% methossilic units.
- Methyl-cellulose and carboxymethyl-cellulose can be converted into gel.
- microcellulose to be vehiculated in pharmaceutical forms suitable for ingestion tablettes, granular or powder form, etc.
- ingestion tablettes, granular or powder form, etc.
- preparations suitable to cover either partially or totally the requirements of alimentary fibres in humans or animals or in preparations to regulate intestinal transit, preferably suitable for the use in all conditions of altered intestinal motility due to an insufficient or viceversa excessive water retention, first in the alimentary bolus and then in stools, where microcellulose affects in a regulatory manner the solid-fluid ratio during intestinal transit.
- Microcrystalline cellulose or microcellulose is a preparation of fragments of cellulose crystallite units in the form of a non fibrosic powder, containing particles in the form of rigid small bars, whose refraction index is 1.55.
- the molecular weight of the basic component, microcellulose can range as required from 10.000 to 300.000, i.e. between a range of numbers of atoms classified from 10 4 to IO 9 , whose dimensions allow a liophile colloidal dispersion.
- Availability of different molecular weights of microcrystalline cellulose allow to graduate the number of molecule in any given unit of weight, thus to improve or reduce the osmolar effect ofthe product. Examples of how microcrystalline cellulose is synthesised are described in US Patents nos. 2,978,476 and US 3,141,875.
- Microcrystalline cellulose or microcellulose is featured by its peculiar property of being slightly soluble in diluted alcaline solutions, whereas it is totally insoluble in acids and does not gelify under any conditions.
- microcellulose is fully inactive in the stomach and just a light solubility can be foreseen in the continuation of the gastrointestinal transit with pH raise. Moreover, unlike methyl- cellulose, microcrystalline cellulose will not dissolve in any water volume.
- microcellulose to obtain a regulatory effect on intestinal motility due to its chemical-physical characteristics. This has the pu ⁇ ose of obviating to the problems caused by alimentary fibres available so far on the market, such as subordination to water volume, digestion of part of their constituents and often unendurable production of large intestinal gas volumes, their chelating effect con pharmaceutical products and some minerals salts.
- microcellulose is provided for use under those conditions where alimentary fibres are not tolerated, being excessively irritant and eliciting a too fast, frequent and irritant intestinal transit of bolus volume. Microcellulose is not digested by mammals because they have no cellulase, i.e. the enzyme required to break beta bonds between D- glucose molecules. For this reason, microcellulose will not cause, as of itself, any problems related to the digestion of sugars contained in the fibres or alimentary fibres. 7
- microcellulose Due to the relatively small molecular size in respect to cellulosic fibres (containing milions of closely interlaced cellulose units for total macroscopic sizes), microcellulose is also featured by a lower water eagerness and unlike water soluble methyl-cellulose it is insoluble in water.
- microcellulose will yield a number of molecules as liophile dispersion to the water available with or contained in the aliments, as a fixed proportion of the water- microcellulose ratio (as it can be easily proved by gradually adding water volumes to a fixed cellulose volume: a progressive reduction of the precipitate will in fact show up with increasing volumes of solvents; however, it will remain a precipitate also with a 1000:1 water-cellulose weight ratio).
- a gradual "bulking" effect will be obtained, which is easily dosable for progressive dose increases.
- microcellulose will develop through its insolubility an efficient absorbing effect in all those conditions where an excessive intestinal transit speed is caused by intestinal inability to reabsorb water.
- This condition occurs and has a clinical significance eg. in the case of irritable colon syndrome, characterized by alternating alvus, i.e. repeated alternation of constipation and stools.
- Such a condition is often related to the intestine intolerance to some sugars available in the aliments that cannot be digested at all, or to an oversensitivity to vegetable long fibers, or both of them.
- the intestinal bacterial flora will rapidly convert lactose into lactic acid, carbon dioxide and water, stressing both the irritant effect and transit speed, and alternating strong abdominal distention and pains. While the therapy will obviously require a reduction or removal of milk products, introduction of microcellulose according to the present invention has a regulatory effect on the bolus and makes it consistent, however it will not lead to the overdistention phenomena as caused by fibres of vegetable origin, right for the limited swelling capacity of microcellulose.
- microcellulose does not contain any constituents capable of a further incentive for bacterial degradation with gas production.
- Microcrystalline cellulose is a polyhydroxyaldheide, thus it has a slight polarity between the terminal portion which is lyophilic and the initial portion which is hydrophilic. In our experiments this characteristic of the molecule allows either an important and irreversible dispersion of oil in water media, or a reduction in capillary water pressures. Thus, reducing the size of oil drops in food introduced by diet and water adhesiveness, the introduction of sufficient amounts of microcrystalline cellulose would improve also gastric emptying. This phenomenon has never been described before. On the contrary, all alimentary fibers are well known and clinically used for the pu ⁇ ose to slow gastric emptying, bloating being the subjective consequence which very frequently leeds to discontinuation of fibers introduction.
- microcellulose vehiculated in pharmaceutical forms for ingestion (tablets, capsules or granular and/or powder form) is indicated as the main or sole active constituent in preparations for use in all conditions of altered intestinal motility due to insufficient or viceversa excessive water presence, first in the alimentary bolus and then in stools. Due to its insoluble characteristics (unlike soluble methyl-cellulose and carboxymethyl-cellulose) that make it an ideal lyophilic colloid, microcellulose develops a regulatory effect on the solid-fluid ratio during intestinal transit. It is apparent how according to the present invention microcellulose is indicated for use as the main or sole active ingredient in preparations adequately covering either partially or totally the requirements of undigested fibres in the alimentary diet of humans and animals.
- microcellulose in this frame can be used as an ideal dietetic integrator in all pathologic conditions where fibres assumption is contraindicated since irritation is caused by an excessive length of fibres.
- microcellulose according to the present invention is indicated as an ideal dietetic integrator in all conditions where the intestinal assumption of fibres should be maintained or increased, but this is contraindicated because of the risk of malabso ⁇ tion induced by them on calcium and iron (eg. osteoporosis, pregnancy, sideropoor anaemia, etc.).
- microcellulose is an ideal integrator of undigested fibres for its dimensional, chemical-physical and organolectic characteristics, having an ideal regulatory effect in all conditions of decreased intestinal motility and above all in all conditions where other undigested fibrous residues are not tolerated and even contraindicated for therapeutic pu ⁇ oses.
- microcellulose can also be used as a constituent for association with other molecules, to modulate the preponderant effect of some substances (eg. a strong hydrophilous effect of methyl-cellulose and psyllium) or stress the reducing tensio-active effect of other substances (eg. symeticone).
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU76232/96A AU7623296A (en) | 1995-11-14 | 1996-11-13 | Microcellulose-based preparations |
EP96939020A EP0861083A1 (en) | 1995-11-14 | 1996-11-13 | Microcellulose-based preparations |
JP9518574A JP2000502048A (en) | 1995-11-14 | 1996-11-13 | Microcellulose preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95TO000917A IT1290792B1 (en) | 1995-11-14 | 1995-11-14 | MICROCELLULOSE BASED PREPARATIONS |
ITTO95A000917 | 1995-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997017976A1 true WO1997017976A1 (en) | 1997-05-22 |
Family
ID=11413961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/004961 WO1997017976A1 (en) | 1995-11-14 | 1996-11-13 | Microcellulose-based preparations |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0861083A1 (en) |
JP (1) | JP2000502048A (en) |
AR (1) | AR008987A1 (en) |
AU (1) | AU7623296A (en) |
IT (1) | IT1290792B1 (en) |
WO (1) | WO1997017976A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993551B2 (en) | 2002-10-16 | 2015-03-31 | Alan Ferguson | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3023104A (en) * | 1960-07-05 | 1962-02-27 | American Viscose Corp | Food compositions incorporating cellulose crystallite aggregates |
EP0317079A2 (en) * | 1987-11-19 | 1989-05-24 | Orlando A. Battista | High-fiber, expandable, dry-mixed compositions |
JPH01319421A (en) * | 1988-06-17 | 1989-12-25 | Hajime Inamoto | Composition for improving constipation, promoting dejection and improving fecal property |
US5342636A (en) * | 1992-05-05 | 1994-08-30 | Bakshi Amarjit S | Process for modifying a fibrous bulking agent |
-
1995
- 1995-11-14 IT IT95TO000917A patent/IT1290792B1/en active IP Right Grant
-
1996
- 1996-11-13 WO PCT/EP1996/004961 patent/WO1997017976A1/en not_active Application Discontinuation
- 1996-11-13 EP EP96939020A patent/EP0861083A1/en not_active Withdrawn
- 1996-11-13 AU AU76232/96A patent/AU7623296A/en not_active Abandoned
- 1996-11-13 JP JP9518574A patent/JP2000502048A/en active Pending
- 1996-11-14 AR ARP960105185A patent/AR008987A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3023104A (en) * | 1960-07-05 | 1962-02-27 | American Viscose Corp | Food compositions incorporating cellulose crystallite aggregates |
EP0317079A2 (en) * | 1987-11-19 | 1989-05-24 | Orlando A. Battista | High-fiber, expandable, dry-mixed compositions |
JPH01319421A (en) * | 1988-06-17 | 1989-12-25 | Hajime Inamoto | Composition for improving constipation, promoting dejection and improving fecal property |
US5342636A (en) * | 1992-05-05 | 1994-08-30 | Bakshi Amarjit S | Process for modifying a fibrous bulking agent |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 014, no. 118 (C - 0697) 6 March 1990 (1990-03-06) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993551B2 (en) | 2002-10-16 | 2015-03-31 | Alan Ferguson | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2000502048A (en) | 2000-02-22 |
EP0861083A1 (en) | 1998-09-02 |
AU7623296A (en) | 1997-06-05 |
AR008987A1 (en) | 2000-03-08 |
IT1290792B1 (en) | 1998-12-10 |
ITTO950917A0 (en) | 1995-11-14 |
ITTO950917A1 (en) | 1997-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Behera et al. | Konjac glucomannan, a promising polysaccharide of Amorphophallus konjac K. Koch in health care | |
Cassidy et al. | Effect of soluble dietary fibre on postprandial blood glucose response and its potential as a functional food ingredient | |
Singh et al. | Prebiotic potential of oligosaccharides: A focus on xylan derived oligosaccharides | |
Zhu et al. | Functional polysaccharides of carob fruit: a review | |
Kumar et al. | Dietary roles of non-starch polysachharides in human nutrition: a review | |
JP5898171B2 (en) | Carbohydrate mixture | |
Rose et al. | Influence of dietary fiber on inflammatory bowel disease and colon cancer: importance of fermentation pattern | |
EP2188315B1 (en) | Method of preparing fibre-containing pectin product and pectin products hereof | |
Qiang et al. | Health benefit application of functional oligosaccharides | |
Brownlee et al. | Alginate as a source of dietary fiber | |
US5840860A (en) | Fatty acid delivery system comprising a hydrolyzable bond | |
US7067498B2 (en) | Polymer controlled induced viscosity fiber system and uses thereof | |
Liu et al. | The physicochemical properties, in vitro binding capacities and in vivo hypocholesterolemic activity of soluble dietary fiber extracted from soy hulls | |
Gomez et al. | Manufacture and properties of glucomannans and glucomannooligosaccharides derived from konjac and other sources | |
Margareta et al. | Importance of processing for physico-chemical and physiological properties of dietary fibre | |
Arora et al. | Plant-based polysaccharides and their health functions | |
WO1997017976A1 (en) | Microcellulose-based preparations | |
Rose et al. | Overview of dietary fiber and its influence on gastrointestinal health | |
Robinson et al. | Nutritional benefits of larch arabinogalactan | |
Meyer et al. | Non‐digestible oligosaccharides and polysaccharides: their physiological effects and health implications | |
WO2010140182A1 (en) | Food compositions comprising flour, glucomannan and a mixture of soluble prebiotic fibres and process for the preparation thereof | |
JP2015514411A (en) | Combination of β-glucan and arabinoxylan | |
Bhat et al. | Cereals as functional ingredients in meat and meat products | |
Purohit et al. | Isabgol: a herbal remedy | |
Rose | Autohydrolytic production of feruloylated arabinoxylan hydrolysates from cereal processing coproducts for food applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 518574 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996939020 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996939020 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996939020 Country of ref document: EP |